2Yeh P, Chen H, Andrews J, et al. DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT) : a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy[ J]. Clin Cancer Res, 2013, 19: 1894-1901.
3Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma [ J ]. N Engl J Med, 2009, 361: 947-957.
4Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus eisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor ( WJTOG3g05 ) : an open label, randomised phase 3 trial [ J ]. Lancet Oncol, 2010, 11 : 121-128.
5Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase Ⅲ, randomised, open- label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) [J]. Ann Oncol, 2013, 24: 1615-1622.
6Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib [ J ]. PLoS Med, 2005, 2: e17.
7Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EMIA-ALK fusion gene in non-small-cell lung cancer [J]. Nature, 2007, 448: 561-566.
8Greulich H, Chen TH, Feng W, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants [ J ]. PLoS Med, 2005,2: e313.
9Tam IY, Leung EL, Tin VP, et al. Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations [J]. Mol Cancer Ther, 2009, 8: 2142-2151.
10Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer[J]. J Clin Invest, 2006, 116: 2695 -2706.
